Guideline Recommendations for Newer NF1-PN Therapies

EP: 1.Genetic And Molecular Mechanisms of NF1

EP: 2.Diagnosis, Epidemiology, And Risk Factors Of NF1-PN

EP: 3.Hallmark Symptoms and Clinical Features of NF1-PN

EP: 4.Quality of Life in Patients With NF1-PN

EP: 5.Key Clinical Considerations in NF1-PN Management

EP: 6.Unmet Needs of Patients Living With NF1-PN

EP: 7.Main Goals in the Management of NF1-PN

EP: 8.Rationale for MEK Inhibitors and Surgery

EP: 9.Selumetinib as a Therapeutic Option for NF1-PN

EP: 10.Examining Combination Therapy In NF1-PN

EP: 11.Barriers to Optimal NF1-PN Care for Patients

EP: 12.Lessons From Previously Used Therapies In NF1-PN

EP: 13.ReNeu Trial & Efficacy of Mirdametinib in NF1-PN

EP: 14.Mirdametinib as a Therapy for Patients With NF1-PN

EP: 15.The Role of Biomarkers in NF1-PN Care

Now Viewing

EP: 16.Guideline Recommendations for Newer NF1-PN Therapies

Summary for Physicians

Current Guideline Recommendations for Mirdametinib
Current guidelines recommend mirdametinib for pediatric patients (2 years and older) with progressive, symptomatic neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN) that causes significant morbidity and is inoperable or difficult to manage surgically. It is considered for patients with tumor growth that impacts function or causes pain, and when other treatment options have been ineffective or are not feasible.

Incorporating Guidelines Into Clinical Practice

In clinical practice, these guidelines should guide decisions on early initiation of mirdametinib for progressive tumors that meet the criteria. Regular monitoring for adverse effects and tumor response is essential to assess treatment efficacy and adjust as needed. Integrating multidisciplinary care teams, including oncologists, pain specialists, and genetic counselors, is crucial for optimizing patient outcomes.